HRP20170905T1 - Antikancerogeni fuzijski protein - Google Patents
Antikancerogeni fuzijski protein Download PDFInfo
- Publication number
- HRP20170905T1 HRP20170905T1 HRP20170905TT HRP20170905T HRP20170905T1 HR P20170905 T1 HRP20170905 T1 HR P20170905T1 HR P20170905T T HRP20170905T T HR P20170905TT HR P20170905 T HRP20170905 T HR P20170905T HR P20170905 T1 HRP20170905 T1 HR P20170905T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- fusion protein
- domain
- sequence
- protein according
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims 14
- 108020001507 fusion proteins Proteins 0.000 title claims 14
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (13)
1. Fuzijski protein koji sadrži:
- domenu (a) koja sadrži funkcionalni fragment sekvence topivog hTRAIL proteina koja počinje s amino kiselinom na položaju ne nižem od hTRAIL95 i sposobna je inducirati apoptotski signal u stanicama sisavaca nakon vezanja na njegove receptore na površini stanica, ili homolog navedenog funkcionalnog fragmenta koji ima barem 70% identičnosti sekvence s navedenim funkcionalnim fragmentom; i
- domenu (b) koja čini sekvencu antiangiogenog efektorskog peptida koja je inhibitor receptora faktora rasta i odabrana je iz skupine koju čine fragmenti faktora rasta koji obuhvaćaju VEGF fragment od SEQ. Br. 17, PDGF fragment od SEQ. Br. 22 i EGF fragment od SEQ. Br. 23;
pri čemu sekvenca domene (b) je spojena na C – terminalni kraj ili N - terminalni kraj domene (a).
2. Fuzijski protein prema zahtjevu 1, naznačen time da domena (a) sadrži fragment sekvence topivog hTRAIL proteina koja počinje s amino kiselinom iz raspona hTRAIL95 do hTRAIL121, uključivo, te završava s amino kiselinom hTRAIL281.
3. Fuzijski protein prema zahtjevu 1 ili 2, naznačen time da je domena (a) odabrana iz skupine koju čine hTRAIL95-281, hTRAIL119-281, hTRAIL120-281 i hTRAIL121-281.
4. Fuzijski protein prema bilo kojem od zahtjeva 1 do 3, naznačen time da fuzijski protein između domene (a) i domene (b) sadrži domenu (c) koja obuhvaća mjesto cijepanja proteaze, odabranu od sekvence koju prepoznaje metaloproteaza MMP, sekvence koju prepoznaje urokinaza uPA, te njihove kombinacije.
5. Fuzijski protein prema zahtjevu 4, naznačen time da sekvenca koju prepoznaje metaloproteaza MMP je SEQ. Br. 24, SEQ. Br. 55 ili SEQ. Br. 56, i sekvenca koju prepoznaje urokinaza uPA je SEQ. Br. 25.
6. Fuzijski protein prema zahtjevu 4 ili 5, naznačen time da je domena (c) kombinacija sekvenci smještenih jedna do druge koje se prepoznaju metaloproteazom MMP i urokinazom uPA.
7. Fuzijski protein u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da protein između domena (a), (b), (c) i/ili (d) dodatno sadrži glicin, glicin-serin ili cistein fleksibilnu steričku poveznicu ili njihove kombinacije.
8. Fuzijski protein prema zahtjevu 7, naznačen time da je fleksibilna sterička poveznica odabrana iz skupine koju čine GG, E, GGGCAAACAAC (SEQ. Br. 26), GGCAAACAAC (SEQ. Br. 27), GGGGG (SEQ. Br. 28), GGGG (SEQ. Br. 29), GGG (SEQ. Br. 30) i GSG (SEQ. Br. 54).
9. Fuzijski protein prema zahtjevu 1 naznačen time da ima sekvencu odabranu iz skupine koju čine SEQ. Br. 1; SEQ. Br. 2; SEQ. Br. 4; SEQ. Br. 5; SEQ. Br. 6; SEQ. Br. 9; SEQ. Br. 10; SEQ. Br. 11; SEQ. Br. 14; SEQ. Br. 15; SEQ. Br. 46; SEQ. Br. 47; SEQ. Br. 48, i SEQ. Br. 49.
10. Fuzijski protein u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je rekombinantni protein.
11. Farmaceutski pripravak, naznačen time da kao aktivni sastojak sadrži fuzijski protein kako je definirano u bilo kojem od zahtjeva 1 do 10, u kombinaciji s farmaceutski prihvatljivim nosačem.
12. Farmaceutski pripravak prema zahtjevu 11, naznačen time da je u obliku za parenteralnu primjenu.
13. Fuzijski protein kako je definirano u bilo kojem od zahtjeva 1 do 10 naznačen time da je za uporabu za liječenje neoplastičnih bolesti kod sisavaca, uključujući ljude.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL393578A PL219845B1 (pl) | 2011-01-05 | 2011-01-05 | Przeciwnowotworowe białko fuzyjne |
PCT/EP2012/050145 WO2012093158A1 (en) | 2011-01-05 | 2012-01-05 | Anticancer fusion protein |
EP12700215.2A EP2661496B1 (en) | 2011-01-05 | 2012-01-05 | Anticancer fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170905T1 true HRP20170905T1 (hr) | 2017-09-08 |
Family
ID=45476512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170905TT HRP20170905T1 (hr) | 2011-01-05 | 2017-06-13 | Antikancerogeni fuzijski protein |
Country Status (25)
Country | Link |
---|---|
US (1) | US9175059B2 (hr) |
EP (1) | EP2661496B1 (hr) |
JP (1) | JP5797773B2 (hr) |
KR (1) | KR101950043B1 (hr) |
CN (1) | CN103228788B (hr) |
AU (1) | AU2012204900B2 (hr) |
BR (1) | BR112013016980B1 (hr) |
CA (1) | CA2814597C (hr) |
CY (1) | CY1119149T1 (hr) |
DK (1) | DK2661496T3 (hr) |
EA (1) | EA025830B1 (hr) |
ES (1) | ES2628377T3 (hr) |
HR (1) | HRP20170905T1 (hr) |
HU (1) | HUE032576T2 (hr) |
IL (1) | IL226205B (hr) |
LT (1) | LT2661496T (hr) |
ME (1) | ME02756B (hr) |
MX (1) | MX339203B (hr) |
PL (2) | PL219845B1 (hr) |
PT (1) | PT2661496T (hr) |
RS (1) | RS56095B1 (hr) |
SG (1) | SG190049A1 (hr) |
SI (1) | SI2661496T1 (hr) |
UA (1) | UA108778C2 (hr) |
WO (1) | WO2012093158A1 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2970487T (lt) | 2013-03-12 | 2020-05-11 | Molecular Templates, Inc. | Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui |
WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
DK2995626T3 (en) | 2013-05-06 | 2018-10-29 | Univ China Pharma | BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF |
CN106103489B (zh) | 2014-01-27 | 2020-10-02 | 分子模板公司 | Mhc i类表位递送多肽 |
US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
JP6735237B2 (ja) | 2014-06-11 | 2020-08-05 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | プロテアーゼ切断耐性、志賀毒素aサブユニットエフェクターポリペプチド及びそれを含む細胞標的化分子 |
AU2016215205B2 (en) | 2015-02-05 | 2021-10-21 | Molecular Templates, Inc. | Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
US10428132B2 (en) | 2015-02-11 | 2019-10-01 | West China Hospital, Sichuan University | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof |
PT3303373T (pt) | 2015-05-30 | 2020-07-14 | Molecular Templates Inc | Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas |
IL302130A (en) | 2016-12-07 | 2023-06-01 | Molecular Templates Inc | Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation |
AU2018213194B2 (en) | 2017-01-25 | 2023-01-12 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes |
KR20200143634A (ko) | 2018-04-17 | 2020-12-24 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU676476B2 (en) | 1992-04-29 | 1997-03-13 | Georgetown University | Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2-receptor |
KR101004174B1 (ko) | 1995-06-29 | 2010-12-24 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
EP0854929A1 (en) * | 1995-09-27 | 1998-07-29 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
DE10247755B4 (de) | 2002-10-14 | 2006-01-19 | Pfizenmaier, Klaus, Prof. Dr. | Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine |
CN1257187C (zh) * | 2003-10-22 | 2006-05-24 | 上海恰尔生物技术有限公司 | 钙网蛋白-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 |
US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
CA2544473C (en) | 2003-11-03 | 2013-08-13 | Beijing Sunbio Biotech Co., Ltd. | A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof |
CN1256347C (zh) * | 2003-12-10 | 2006-05-17 | 中国人民解放军第二军医大学 | 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 |
ATE540318T1 (de) | 2005-08-16 | 2012-01-15 | Genentech Inc | Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe |
WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
GB0723059D0 (en) | 2007-11-23 | 2008-01-02 | Nat Univ Ireland | Improved cytokine design |
GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
WO2009140469A2 (en) | 2008-05-14 | 2009-11-19 | Genentech, Inc. | Methods of using apo2l/trail to treat cancer |
US8039437B2 (en) * | 2008-06-30 | 2011-10-18 | The Trustees Of The University Of Pennsylvania | Fn14/TRAIL fusion proteins |
PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
HUE027068T2 (en) * | 2010-12-03 | 2016-08-29 | Adamed Sp Zoo | Anti-cancer fusion protein |
-
2011
- 2011-01-05 PL PL393578A patent/PL219845B1/pl unknown
-
2012
- 2012-01-05 JP JP2013547859A patent/JP5797773B2/ja active Active
- 2012-01-05 PT PT127002152T patent/PT2661496T/pt unknown
- 2012-01-05 HU HUE12700215A patent/HUE032576T2/en unknown
- 2012-01-05 AU AU2012204900A patent/AU2012204900B2/en active Active
- 2012-01-05 US US13/978,090 patent/US9175059B2/en active Active
- 2012-01-05 SG SG2013032768A patent/SG190049A1/en unknown
- 2012-01-05 PL PL12700215T patent/PL2661496T3/pl unknown
- 2012-01-05 EA EA201391005A patent/EA025830B1/ru unknown
- 2012-01-05 BR BR112013016980-0A patent/BR112013016980B1/pt active IP Right Grant
- 2012-01-05 CN CN201280003863.3A patent/CN103228788B/zh active Active
- 2012-01-05 LT LTEP12700215.2T patent/LT2661496T/lt unknown
- 2012-01-05 ES ES12700215.2T patent/ES2628377T3/es active Active
- 2012-01-05 RS RS20170597A patent/RS56095B1/sr unknown
- 2012-01-05 CA CA2814597A patent/CA2814597C/en active Active
- 2012-01-05 KR KR1020137020558A patent/KR101950043B1/ko active IP Right Grant
- 2012-01-05 ME MEP-2017-131A patent/ME02756B/me unknown
- 2012-01-05 WO PCT/EP2012/050145 patent/WO2012093158A1/en active Application Filing
- 2012-01-05 SI SI201230978T patent/SI2661496T1/sl unknown
- 2012-01-05 MX MX2013007872A patent/MX339203B/es active IP Right Grant
- 2012-01-05 EP EP12700215.2A patent/EP2661496B1/en active Active
- 2012-01-05 DK DK12700215.2T patent/DK2661496T3/en active
- 2012-05-01 UA UAA201309548A patent/UA108778C2/ru unknown
-
2013
- 2013-05-07 IL IL226205A patent/IL226205B/en active IP Right Grant
-
2017
- 2017-06-13 HR HRP20170905TT patent/HRP20170905T1/hr unknown
- 2017-06-15 CY CY20171100632T patent/CY1119149T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170905T1 (hr) | Antikancerogeni fuzijski protein | |
HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
HRP20200503T1 (hr) | Fuzijski proteini | |
HRP20202024T1 (hr) | Cd3-vežuća domena | |
HRP20231118T1 (hr) | Sintetizirani polipeptidi koji vežu transferinske receptore | |
HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
HRP20210411T1 (hr) | Jednoručni receptori fuzijskih proteina tipa i i tipa ii i njihove uporabe | |
PE20090763A1 (es) | Polipetidos, dominios variables de anticuerpos y antagonistas | |
WO2015188132A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
HRP20231496T1 (hr) | Cistein proteaza | |
BR112013029525A8 (pt) | Proteínas de fusão terapêuticas | |
HRP20180012T1 (hr) | Antikancerogeni fuzijski protein | |
PH12017500866A1 (en) | Targeted xten conjugate compositions and methods of making same | |
HRP20170535T1 (hr) | Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene | |
HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
JP2013172734A5 (hr) | ||
PE20141454A1 (es) | Inmunotoxina recombinante dirigida a la mesotelina | |
AR085984A1 (es) | Moleculas de union biespecificas que se unen al factor de crecimiento endotelial (vegf) y a la angiopoyetina 2 (ang2) | |
SG10201811172PA (en) | A peptide mixture | |
AR078515A1 (es) | Moleculas de union biespecificas de union a vegf (factor de crecimiento endotelial vascular) y a dll4 (ligando 4 de tipo delta) para la terapia anti-angiogenesis | |
MX2016015868A (es) | Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina. | |
EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
JP2015504052A5 (hr) |